Close Menu

NEW YORK – Within less than a year, diagnostics firm Oncocyte has transformed from a pre-commercial company with a single test in development to a commercially operating diagnostics provider with three tests in its pipeline, the two newest of which have now beat its original DetermaVu in the race to the clinic.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.